Status:
COMPLETED
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.
Lead Sponsor:
Helwan University
Conditions:
Liver Transplant Rejection
Eligibility:
All Genders
20-64 years
Brief Summary
Our study aimed at studying the impact of gene polymorphism of NFKBIA and PTPN22 genes on rejection episodes in liver transplant Egyptian recipients. Also assess patients' factors associated with graf...
Detailed Description
Liver transplantation is considered an effective therapy for severe liver disease, but graft dysfunction occurs in up to 13% of patients during the first year following transplantation, and rises to 3...
Eligibility Criteria
Inclusion
- Adult Patients with ESLD were subjected to living donor liver transplantation due to different etiologies including hepatitis C virus (HCV), hepatitis B virus (HBV), autoimmune hepatitis (AIH), portal venous thrombosis (PVT), cryptogenic hepatitis, Primary sclerosing cholangitis(PSC), hepatocellular and carcinoma(HCC) were eligible for the study. Recipients received calcineurin inhibitors either tacrolimus or cyclosporine as primary immunosuppressant ± MMF or evorilumus ± MMF immediately after transplantation.
Exclusion
- Patients were excluded if they had multi-organ transplantation, had previously received a liver transplant, or were receiving an ABO-incompatible transplant.
Key Trial Info
Start Date :
March 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 24 2023
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT06060808
Start Date
March 15 2021
End Date
July 24 2023
Last Update
September 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sara Mohamed Mohamed
Cairo, Egypt